Altimmune (MEX:ALT1) Additional Paid-In Capital : MXN14,896.07 Mil(As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Altimmune Additional Paid-In Capital?

Altimmune's quarterly additional paid-in capital increased from Sep. 2024 (MXN13,319.01 Mil) to Dec. 2024 (MXN14,387.60 Mil) and increased from Dec. 2024 (MXN14,387.60 Mil) to Mar. 2025 (MXN14,896.07 Mil).

Altimmune's annual additional paid-in capital increased from Dec. 2022 (MXN11,081.51 Mil) to Dec. 2023 (MXN11,295.12 Mil) and increased from Dec. 2023 (MXN11,295.12 Mil) to Dec. 2024 (MXN14,387.60 Mil).

Altimmune Additional Paid-In Capital Historical Data

The historical data trend for Altimmune's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Additional Paid-In Capital Chart

Altimmune Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

8,301.69

10,202.47

11,081.51

11,295.12

14,387.60

Altimmune Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial															11,099.84	12,330.91	13,319.01	14,387.60	14,896.07

Altimmune Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Altimmune Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Altimmune's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Altimmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (MEX:ALT1) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ALT:USA 0A4C:UK 3G0:Germany 3G0:Germany

Address

910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878

Website

https://www.altimmune.com

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Headlines

No Headlines